ABSTRACT

KEYWORDS

REFERENCES

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006; 27: 397-412.

2. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, et al. The Burden of obstructive lung disease initiative (BOLD): Rationale and designs. J COPD 2005; 2: 277-283.

3. Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004; 9; 458-65.

4. Menezes AM, Pérez-Padilla R, Jardim JR, Muino A, Lopez MV, et al; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American Cities (the PLATINO study): a prevalence study. Lancet 2005; 366:1875-1881.

5. Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, et al. Post-bronchodilator spirometry reference values in adults and implication for disease management. Am J Respir Crit Care Med 2006; 173: 1316-1325.

6. Hnizdo E, Glindmeyer HW, Petsonk EL, Enright P, Buis AS. Case definitions for chronic obstructive pulmonary disease. J COPD 2006; 3: 95-100.

7. Pawel RA, Rabe KF Burden and clinical features of chronic obstructive pulmonary disease. Lancet 2004; 364:613-620.

8. Instituto Nacional de Geografía e Informática (INEGI). http://www.inegi.gob.mx/lib/estadisticas.asp?s=inegi

9. Pérez-Padilla R, Regalado J, Vedal S, Pare P, Chapela R, et al. Exposure to biomass smoke and chronic airway disease in mexican woman. A case-control study. Am J Respir Crit Care Med 1996; 154: 701-706.

10. Encuesta censal del cuestionario ampliado. XII Censo de Población y vivienda 2000. INEGI. http:// www. conapo.gob.mx

11. Ramirez-Venegas A, Sansores RH, Pérez-Padilla R, Regalado J, Velazquez A, et al. Survival of Patients with Chronic Obstructive Pulmonary Disease due to biomass smoke and tobacco. Am J Resp Crit Care Med 2006; 173: 393-397.

12. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United Status: Data from the first national health and nutrition examination survey follow up study. Thorax 2003: 58: 388-393.

13. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75-81.

14. Calverley P, Pauwels R, Vestbo J, Jones P. Combined salmeterol and fluticasona in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003 8; 361: 449-456.

15. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.

16. Carter R, Blevins W, Stocks J, Klein R, Idell S. Cost and quality issues related to the management of COPD. Sem Resp Crit Med 1999; 20: 199-212.

17. Grasso ME, Weller WE, Shaffer TJ, Diette GB. Anderson GF. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998:158:133-138.

18. Foucher R, Baudouin N, Merati M, Pitard A, Bonniaud P, et al. Relative survival analysis of 252 patients with COPD receiving long-term oxygen therapy. Chest 1998; 113: 1580-1587.

19. Costos en atención médica atribuibles al tabaquismo, en el IMSS Morelos. Reynales-Shigematsu LM, Juarez-Márquez SA, Valdes-Salgado R. Salud Pública Mex 2005; 47: 451-457.